Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Netherlands-based drug delivery company OctoPlus has signed a pharmaceutical development contract with Belgium-based biotechnology company Galapagos. The undisclosed contract value is expected to contribute to OctoPlus's annual revenues.
Subscribe to our email newsletter
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos’s Phase II study of Nanocort. OctoPlus said that it has progressed the scale-up and robustness of the production process of this complex liposomal product.
Nanocort is a patented liposome-formulation of prednisolone to treat inflammatory diseases, in particular for the acute treatment of flares in rheumatoid arthritis.
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that have fewer side effects, and improved patient convenience. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, drugs, and vaccines for its clients.
Galapagos is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. It has established an alliances with GSK, Janssen Pharmaceutica, Eli Lilly and Merck. Galapagos is also developing new antibody therapies in bone and joint diseases in alliance with MorphoSys. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.